Other
2029
Merck & Co. 2029 increased by 40.0% to $2.10B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 40.0%, from $1.50B to $2.10B. Over 5 years (FY 2020 to FY 2025), 2029 shows an upward trend with a 4.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026
How to read this metric
Consistent, manageable maturity amounts suggest stable financial health and effective capital management.
Detailed definition
This represents the specific portion of long-term debt principal scheduled for repayment during the 2029 fiscal year. It...
Peer comparison
Debt maturity schedules are standard disclosures for capital-intensive firms to demonstrate long-term solvency.
Metric ID:
other_long_term_debt_maturities_repayments_of_principal__81682fHistorical Data
5 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.30B | $2.50B | $2.20B | $1.50B | $2.10B |
| QoQ Change | — | +92.3% | -12.0% | -31.8% | +40.0% |
| YoY Change | — | +92.3% | -12.0% | -31.8% | +40.0% |
Range$1.30B – $2.50B
CAGR+61.5%
Avg YoY Growth+22.1%
Median YoY Growth+14.0%
2029 at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s 2029?
- Merck & Co. (MRK) reported 2029 of $2.10B in Q4 2025.
- How has Merck & Co.'s 2029 changed year-over-year?
- Merck & Co.'s 2029 increased by 40.0% year-over-year, from $1.50B to $2.10B.
- What is the long-term trend for Merck & Co.'s 2029?
- Over 5 years (2020 to 2025), Merck & Co.'s 2029 has grown at a 4.3% compound annual growth rate (CAGR), from $1.70B to $2.10B.
- What does 2029 mean?
- The amount of long-term debt principal that must be repaid in 2029.